multiple sclerosis
Use of Genzyme’s MS drug Lemtrada restricted under ongoing EMA safety review
April 16, 2019Manufacturing and Production, Sales and Marketing EMA, Genzyme, Lemtrada, multiple sclerosis, pharma
The EMA has launched a review into Genzyme’s multiple sclerosis drug Lemtrada (alemtuzumab) after reports emerged of treatment-related safety issues …
Novartis’ new MS drug to cost $88,000 a year
March 27, 2019Research and Development, Sales and Marketing FDA, MS, Novartis, Novartis pharmaceuticals, multiple sclerosis
Paul Hudson, the CEO of Swiss firm Novartis Pharmaceuticals has said the company’s newly approved multiple sclerosis (MS) drug will …
Novartis’ Gilenya scores paediatric EU approval for advanced relapsing-remitting MS
November 29, 2018Sales and Marketing Europe, Novartis, UK, multiple sclerosis, pharma
Novartis has announced that Gilenya (fingolimod) has received marketing authorisation from the European Commission for the treatment of relapsing-remitting forms …
Roche’s Ocrevus shows earlier, better outcomes in primary progressive and relapsing MS
October 11, 2018Research and Development Ocrevus, Roche, multiple sclerosis, pharma
Roche has unveiled new five-year data from three Phase 3 open-label extension studies investigating the efficacy of Ocrevus (ocrelizumab) in …
NICE rejects Roche’s Ocrevus in primary progressive multiple sclerosis
September 10, 2018Sales and Marketing NICE, Ocrevus, Roche, UK, multiple sclerosis, pharma
Of the 100,000 MS patients in England, around one in eight have the primary progressive form (PPMS), which brings debilitating …
US Congressman arrested over insider trading in biopharma firm
August 9, 2018Research and Development, Sales and Marketing Chris Collins, Innate, Innate Immunotherapeutics, US, congress, multiple sclerosis, pharma
A Republican Congressman has been arrested by the FBI over on charges of insider trading with shares in Australian biopharmaceutical …
Insider Interview: Biosimilars to balance the books
July 9, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Mylan, bisoimilars, multiple sclerosis
Jean-Yves Brault, Country Manager at Mylan UK, discusses how biosimilars are going to play an important role in driving down …
Top Ten most popular articles on Pharmafile.com this week
June 29, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing HIV, J&J, JJ, Remicade, Roche, biosimilar Amgen, lung cancer, multiple sclerosis, pharma
Summer seems to be in full swing as we reach the end of June, so it’s time to look back …
Roche’s Ocrevus cleared for NHS use in relapsing-remitting MS
June 22, 2018Medical Communications, Sales and Marketing MS, NICE, UK, multiple sclerosis, pharma
Roche and multiple sclerosis (MS) patients across England and Wales are celebrating the news that healthcare watchdog NICE has recommended …
Roche’s Ocrevus extends time-to-wheelchair by 7 years in progressive MS patients
June 14, 2018Research and Development Ocrevus, Roche, multiple sclerosis, pharma
Roche has lifted the curtain on more promising data at Phase 3 for its humanised anti-CD20 monoclonal antibody Ocrevus (ocrelizumab), …
EMA review confirms risks of Abbvie and Biogen’s Zinbryta outweigh benefits
May 21, 2018Research and Development, Sales and Marketing EMA, Europe, European Commission, PRAC, multiple sclerosis, pharma, zinbryta
The EMA has judged that the benefits offered by Zinbryta (daclizumab), Abbvie and Biogen’s humanised IgG1 monoclonal antibody for the …
FDA awards first paediatric MS approval to Novartis’ Gilenya
May 14, 2018Sales and Marketing FDA, gilenya, multiple sclerosis, pharma
The FDA has awarded approval for what it says is its first drug for the treatment of multiple sclerosis (MS) …
Roche suffers Ocrevus knockback by NICE
April 6, 2018Medical Communications, Sales and Marketing Ocrevus, Roche, biotech, drugs, multiple sclerosis, pharma, pharmaceutical
Roche’s multiple sclerosis drug, Ocrevus (ocrelizumab), has been a big new growth driver for the company, especially in the US, …
Top Ten most popular articles on Pharmafile.com this week
March 23, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Canada, Celgene, Lundbeck, Marijuana, Novartis, Roche, Vertex, brexit, cannabis, multiple sclerosis, neuroscience, pharma
As me move startlingly quickly towards Easter, it’s time for another Top Ten rundown. This week, Celgene surprised the industry …
“Game-changer” stem cell transplant shows strength in multiple sclerosis
March 19, 2018Research and Development, Sales and Marketing Stem cells, multiple sclerosis, pharma
A new stem cell transplant is being hailed as a “game-changer” in the treatment of multiple sclerosis (MS) after an …
